Global Brain has invested in OneHealthCompany, Inc., the leading pet precision health company

Global Brain has invested in OneHealthCompany, Inc. (The One Health Company), a biotech startup and leading pet precision health company, through its GB-VIII Growth Fund Investment Limited Partnership (GB-VIII).

The company’s flagship product, FidoCure®, is the first of its kind, a cutting-edge precision medicine platform with unparalleled algorithmic driven diagnostics, that was created to improve outcomes in dogs with cancer. The FidoCure® Next Generation DNA Sequencing Test helps in identifying the genetic mutations that cause cancer in dogs and matches them to individualized treatment with targeted therapies. FidoCure® leverages the drugs that have been approved for human use, with additional data specific to canine cancer. With FidoCure®, dogs with cancer receive access to the latest scientific advances in cancer care, from tests to treatment.

There are roughly six million new cancer diagnoses in dogs each year, and approximately one in three dogs will develop cancer during their lifetime. However, the treatments available for canine cancer (mainly chemotherapy) have not changed in the last 30 years. The standard cancer drugs in the market cost $6,000-$10,000 and often have poor outcomes. Additionally, wide-scale access to specialty care is an ongoing issue in veterinary medicine, especially in canine oncology. It is The One Health Company’s mission to change this by more broadly delivering streamlined access to cutting-edge cancer care.

The One Health Company is the market leader and first company in the world to analyze canine cancer at the genetic level, bringing the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. Approximately 3,000 dogs diagnosed with cancer have used the precision medicine platform, resulting in the largest proprietary canine cancer dataset in the world.

By teaming up with world-leading healthcare AI researchers at Stanford University and ~350 oncologists and specialists, The One Health Company has developed proprietary algorithms and treatment methods that have improved the survival time for dogs with cancer by combining drugs and genomic analysis. Learn more at fidocure.com.

Global Brain has invested in The One Health Company because of its evidence-based R&D capability, talented management team, and the platform's tremendous market potential with high versatility applicable to various types of compound pharmaceutical applications. FidoCure® is backed by premier biotech investors including Polaris Partners, A16Z, Y Combinator and Global Brain. Global Brain will contribute to the business growth of The One Health Company in collaboration with our network of Japanese and overseas pharmaceuticals.